WO2002020571A3 - Attenuated hiv strains and use thereof - Google Patents

Attenuated hiv strains and use thereof Download PDF

Info

Publication number
WO2002020571A3
WO2002020571A3 PCT/EP2001/010244 EP0110244W WO0220571A3 WO 2002020571 A3 WO2002020571 A3 WO 2002020571A3 EP 0110244 W EP0110244 W EP 0110244W WO 0220571 A3 WO0220571 A3 WO 0220571A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hiv strains
immunodeficiency virus
attenuated hiv
human immunodeficiency
Prior art date
Application number
PCT/EP2001/010244
Other languages
French (fr)
Other versions
WO2002020571A2 (en
Inventor
Jaap Goudsmit
Marion Cornelissen
Original Assignee
Biomerieux B V A
Jaap Goudsmit
Marion Cornelissen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux B V A, Jaap Goudsmit, Marion Cornelissen filed Critical Biomerieux B V A
Priority to EP01982248A priority Critical patent/EP1315799A2/en
Priority to AU2002213882A priority patent/AU2002213882A1/en
Publication of WO2002020571A2 publication Critical patent/WO2002020571A2/en
Publication of WO2002020571A3 publication Critical patent/WO2002020571A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Abstract

The invention provides an isolated human immunodeficiency virus, comprising at least one non revertant mutation capable of delaying or diminishing the pathological behavior of said immunodeficiency virus when compared to a human immunodeficiency virus not having at least one such a mutation. A virus of the invention can be used for the preparation of a vaccine for Aids. Said virus can also be used for diagnostic assays in HIV-infected patients.
PCT/EP2001/010244 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof WO2002020571A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01982248A EP1315799A2 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof
AU2002213882A AU2002213882A1 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00203116.9 2000-09-08
EP00203116 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002020571A2 WO2002020571A2 (en) 2002-03-14
WO2002020571A3 true WO2002020571A3 (en) 2003-03-13

Family

ID=8171998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010244 WO2002020571A2 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof

Country Status (3)

Country Link
EP (1) EP1315799A2 (en)
AU (1) AU2002213882A1 (en)
WO (1) WO2002020571A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US8206913B1 (en) 2003-03-07 2012-06-26 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process
WO2004081225A2 (en) 2003-03-07 2004-09-23 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a dna polymerization process
US8440404B2 (en) 2004-03-08 2013-05-14 Rubicon Genomics Methods and compositions for generating and amplifying DNA libraries for sensitive detection and analysis of DNA methylation
EP1924705A1 (en) 2005-08-02 2008-05-28 Rubicon Genomics, Inc. Isolation of cpg islands by thermal segregation and enzymatic selection-amplification method
EP1924704B1 (en) 2005-08-02 2011-05-25 Rubicon Genomics, Inc. Compositions and methods for processing and amplification of dna, including using multiple enzymes in a single reaction
CA2631881C (en) * 2005-12-07 2015-03-24 Tibotec Pharmaceuticals Ltd. Methods, plasmid vectors and primers for assessing hiv viral fitness
EP2748320B1 (en) * 2011-08-24 2018-06-13 Grifols Therapeutics LLC Compositions and methods for nucleic acid hybridization
WO2016172465A1 (en) * 2015-04-24 2016-10-27 The Johns Hopkins University Compositions and methods related to characterizing proviral reservoirs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017825A1 (en) * 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017825A1 (en) * 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AAVV: "Human Retroviruses and AIDS Compendium, Part III", 1999, LOS ALAMOS NATIONAL LABORATORY, USA, XP002209704 *
ALEXANDER L. ET AL.: "Unusual polymorphism in Human Immunodeficiency Virus Type 1 associated with nonprogressive infection.", J. VIROL., vol. 74, no. 9, May 2000 (2000-05-01), pages 4361 - 4376, XP002159810 *
CASELLA C.R. ET AL.: "Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication", VIROLOGY, vol. 228, 1997, pages 294 - 306, XP002159813 *
DATABASE NCBI [online] 23 November 1999 (1999-11-23), "HIV1 gag protein variant", XP002209705, retrieved from NCBI Database accession no. AAD41167 *
DATABASE NCBI [online] IWATANI: "HIV1 Gag variant", XP002209760, retrieved from NCBI Database accession no. BAA12996 *
FURUTA R.A. ET AL.: "HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases", FEBS LETTERS, vol. 415, 1997, pages 231 - 234, XP002159812 *
WANG C.T. ET AL.: "Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release.", J. VIROLOGY, vol. 72, no. 10, October 1998 (1998-10-01), pages 7950 - 7959, XP002159811 *

Also Published As

Publication number Publication date
AU2002213882A1 (en) 2002-03-22
WO2002020571A2 (en) 2002-03-14
EP1315799A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
ATE362379T1 (en) INDUCTION OF REV- AND TAT-SPECIFIC CYTOTOXIC T CELLS FOR PREVENTION AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION
WO2001054719A3 (en) Vaccine for the prophylactic or therapeutic immunization against hiv
EP2130921A3 (en) Vaccine for prevention and treatment of hiv-infection
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
EP1375652A3 (en) Oral compositions for HIV-Infected Subjects
WO2002087614A3 (en) Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2002020571A3 (en) Attenuated hiv strains and use thereof
WO2000053213A3 (en) Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use
WO2002036771A3 (en) Imaging, diagnosis and treatment of disease
WO2000061067A3 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
FR2756843B1 (en) NON-M NON-O HIV-1 STRAINS, FRAGMENTS AND APPLICATIONS
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
Csillag HIV-1 subtype C in Brazil.
WO2004053100A3 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
WO2002048338A3 (en) Yeast strain for testing the geno- and cytotoxicity of complex environmental contamination
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
Ali et al. Understanding the HIV/AIDS context in Pakistan
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
TW200621800A (en) Human immunodeficiency virus vaccine
HUP0202389A2 (en) Inactivated vaccine against feline calicivirus disease
Unit et al. Operational characteristics of commercially available assays to detect antibodies to HIV-1 and/or HIV-2 in human sera: report 11

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001982248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001982248

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001982248

Country of ref document: EP